Last reviewed · How we verify
JKN2301 Dry Suspension — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
JKN2301 Dry Suspension (JKN2301 Dry Suspension) — Joincare Pharmaceutical Group Industry Co., Ltd. JKN2301 is an investigational dry suspension formulation designed to improve bioavailability and patient compliance for an undisclosed active pharmaceutical ingredient.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JKN2301 Dry Suspension TARGET | JKN2301 Dry Suspension | Joincare Pharmaceutical Group Industry Co., Ltd | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JKN2301 Dry Suspension CI watch — RSS
- JKN2301 Dry Suspension CI watch — Atom
- JKN2301 Dry Suspension CI watch — JSON
- JKN2301 Dry Suspension alone — RSS
Cite this brief
Drug Landscape (2026). JKN2301 Dry Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/jkn2301-dry-suspension. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab